cobenfy bristol myers squibb news

Cobenfy Approval Brings 20% Upside To Bristol Myers Squibb Stock

This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic drugs.

Seeking Alpha · 2d

Bristol-Myers Squibb Likely To Revalue Higher Following New Drug Approval

Bristol-Myers Squibb's stock is set to rise with FDA approvals, acquisitions, and a strong oncology portfolio, despite potential risks. Read more on BMY here.

Investopedia on MSN · 3d

Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets FDA Approval

Key Takeaways Bristol Myers Squibb's drug to treat schizophrenia was approved for use by the Food and Drug Administration.The pharmaceutical firm called Cobenfy the first new treatment for the illness in decades.

16m

Bristol Myers beats $6.4 billion lawsuit over delayed cancer drug

U.S. District Judge Jesse Furman in Manhattan said UMB Bank was never properly appointed trustee for shareholders owning ...

bovnews3h

BMY’s Latest Twist: What’s Fueling the Unexpected Shifts in Bristol-Myers Squibb Co’s Stock Price?

On Friday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $50.91 which represents a slight increase of $0.79 or 1.58% from the prior close of $50.12. The stock opened at ...

Bristol-Myers Squibb: Hold Rating Amid New Schizophrenia Drug Launch and Patent Expiries

Analyst Evan Seigerman from BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) and increased the price ...

Business Wire2d

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s COBENFY™ (xanomeline and trospium chloride), a First-In-Class Muscarinic Agonist for the Treatment of ...

U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results